Victorian Biotech company fast tracks US licensing agreement
|
12 February 2008
|
Sienna Cancer Diagnostics, a Melbourne diagnostic technology firm, has signed a license agreement with Californian biopharmaceutical company Geron Corp. The agreement will allow Sienna access to critical granted patents and intellectual property related to the detection or measurement of telomerase activity, an enzyme active in most cancer cells. Geron is a leader in biopharmaceutical development for the treatment of cancer and chronic degenerative diseases.
|
The license agreement is yet another significant deal between an innovative Victorian company and a US entity fostered in conjunction with the Victorian Government’s technology commercialisation program, VicStart. The program has engaged the US-based Australian, New Zealand, American (ANZA) Technology Network to mentor companies through its Fast Track program, which assists Australian CEOs and senior level executives to navigate the challenging US business terrain in order to increase sales, form partnerships and raise venture capital.
Since the inception of ANZA’s Fast Track program in Australia in late 2006, 22 companies have been making inroads into the US marketplace. More than US$10 million in equity funding has been raised and a number of significant partnerships with US entities have been forged.
For more information about the ANZA Fast Track program, visit
http://www.anzatechnet.com
|
